Theralase Reports Interim Phase II NMIBC Results, Plans 2027 Submissions
The company reported an approximately two-thirds complete response rate and a median response duration of 14.9 months, with treatment-emergent adverse events noted. Enrollment is complete; Theralase plans NDS/NDA submissions, with marketing decisions anticipated in 2027.